OCGNOcugen, Inc.

$578M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M

Gross Profit

$6M100.0% margin

Operating Income

-$9M-142.9% margin

Net Income

-$9M-157.3% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

+63.2%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$65M

Total Liabilities

$24M

Stockholders' Equity

$41M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$0	—
Gross Profit	$6M	$0	—
Operating Income	-$9M	-$24M	+64.3%
Net Income	-$9M	-$22M	+56.7%

OCGN Q4 2023 Earnings — Ocugen, Inc. Revenue & Financial Results | Market Cap Arena